JP5183064B2 - 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体 - Google Patents

甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体 Download PDF

Info

Publication number
JP5183064B2
JP5183064B2 JP2006518782A JP2006518782A JP5183064B2 JP 5183064 B2 JP5183064 B2 JP 5183064B2 JP 2006518782 A JP2006518782 A JP 2006518782A JP 2006518782 A JP2006518782 A JP 2006518782A JP 5183064 B2 JP5183064 B2 JP 5183064B2
Authority
JP
Japan
Prior art keywords
dsrna
shrimp
gene
virus
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006518782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530414A5 (cg-RX-API-DMAC7.html
JP2007530414A (ja
Inventor
パウル グロスス
グレゴリイ ワルル
ロベルト チャプマン
クライグ ブロウデイ
ジャビエル ロバリノ
Original Assignee
エムユーエスシー ファウンデイション フォー リサーチ デべロップメント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムユーエスシー ファウンデイション フォー リサーチ デべロップメント filed Critical エムユーエスシー ファウンデイション フォー リサーチ デべロップメント
Publication of JP2007530414A publication Critical patent/JP2007530414A/ja
Publication of JP2007530414A5 publication Critical patent/JP2007530414A5/ja
Application granted granted Critical
Publication of JP5183064B2 publication Critical patent/JP5183064B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
JP2006518782A 2003-07-02 2004-07-02 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体 Expired - Fee Related JP5183064B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US48453103P 2003-07-02 2003-07-02
US60/484,531 2003-07-02
US49860303P 2003-08-29 2003-08-29
US60/498,603 2003-08-29
US50571403P 2003-09-25 2003-09-25
US60/505,714 2003-09-25
US56429504P 2004-04-22 2004-04-22
US60/564,295 2004-04-22
PCT/US2004/021271 WO2005005613A2 (en) 2003-07-02 2004-07-02 Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011179435A Division JP2012036187A (ja) 2003-07-02 2011-08-19 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体

Publications (3)

Publication Number Publication Date
JP2007530414A JP2007530414A (ja) 2007-11-01
JP2007530414A5 JP2007530414A5 (cg-RX-API-DMAC7.html) 2012-12-20
JP5183064B2 true JP5183064B2 (ja) 2013-04-17

Family

ID=34069336

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006518782A Expired - Fee Related JP5183064B2 (ja) 2003-07-02 2004-07-02 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体
JP2011179435A Pending JP2012036187A (ja) 2003-07-02 2011-08-19 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011179435A Pending JP2012036187A (ja) 2003-07-02 2011-08-19 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体

Country Status (4)

Country Link
US (1) US8633028B2 (cg-RX-API-DMAC7.html)
JP (2) JP5183064B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412282A (cg-RX-API-DMAC7.html)
WO (1) WO2005005613A2 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ582988A (en) 2004-10-21 2011-07-29 Venganza Inc Methods and materials for conferring resistance to pests and pathogens of plants
CN100485036C (zh) * 2005-09-19 2009-05-06 中国科学院海洋研究所 一种中国明对虾抗菌蛋白基因及重组表达和应用
FR2908136A1 (fr) * 2006-11-07 2008-05-09 Ifremer Utilisation de peptides antimicrobiens comme marqueurs de resistance aux infections bacteriennes chez les crevettes peneides
US8097712B2 (en) * 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
FR2926367B1 (fr) * 2008-01-10 2013-01-04 Novaleads Procede fluorimetrique pour evaluer l'influence d'une condition sur un echantillon biologique et ses applications.
US9049850B2 (en) * 2008-02-04 2015-06-09 Ben-Gurion University Of The Negev Research And Development Authority Insulin-like gene of prawns and uses thereof
US8440878B2 (en) 2008-02-04 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Insulin-like gene in prawns and uses thereof
CN101617638B (zh) * 2008-07-04 2011-08-31 中国科学院海洋研究所 一种三疣梭子蟹抗病品系的构建方法
EP2427180B1 (en) 2009-05-05 2016-04-13 Beeologics Inc. Prevention and treatment of nosema disease in bees
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
CA2820536A1 (en) * 2010-10-22 2012-04-26 Donald Danforth Plant Science Center Control of pathogens and parasites
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
CN102816815A (zh) * 2012-03-30 2012-12-12 浙江海洋学院 重组抗菌肽rCrustinI的酵母发酵生产方法
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN102787073B (zh) * 2012-07-13 2014-05-14 苏州大学 一种构建转基因家蚕微孢子虫的方法
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
WO2015051318A1 (en) 2013-10-04 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
EP3420809A1 (en) 2014-04-01 2019-01-02 Monsanto Technology LLC Compositions and methods for controlling insect pests
CN114009454A (zh) 2014-07-29 2022-02-08 孟山都技术公司 用于控制昆虫害虫的组合物和方法
RU2723049C2 (ru) 2015-01-22 2020-06-08 Монсанто Текнолоджи Ллс Композиции и способы борьбы с leptinotarsa
AU2016291813B2 (en) * 2015-07-14 2022-09-01 Transalgae Israel Ltd. Transgenic microalgae and use thereof as a feed for delivery of interfering RNA molecules
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
WO2017180616A1 (en) * 2016-04-11 2017-10-19 Microsynbiotix, Ltd. Dna constructs for manufacturing bio-therapeutic polypeptides for use in animal vaccines and therapeutics
BR112018071997A2 (pt) 2016-04-26 2019-02-12 Viaqua Therapeutics Ltd nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
TWI605816B (zh) * 2016-11-02 2017-11-21 國立屏東科技大學 針對酪氨酸羥化酶之雙股rna的用途
US11446339B2 (en) 2017-03-31 2022-09-20 Pebble Labs Inc. System for the biocontrol of white spot syndrome virus (WSSV) in aquaculture
WO2018184029A1 (en) 2017-03-31 2018-10-04 Pebble Labs, Inc. Novel system for the biocontrol of pathogens in aquaculture and other animal systems
CN106973864A (zh) * 2017-04-25 2017-07-25 遵义医学院 一种适用于白背飞虱注射法rna干扰实验的饲养装置及其使用方法
CN106942162A (zh) * 2017-04-25 2017-07-14 遵义医学院 一种适用于白背飞虱饲喂法rna干扰实验的装置及其使用方法
MX2020001574A (es) 2017-08-07 2020-09-03 Pebble Labs Usa Inc Sistemas y metodos para el control de la enfermedad de necrosis hepatopancreatica aguda.
CN109479899A (zh) * 2018-09-30 2019-03-19 中国农业科学院植物保护研究所 鞘翅目金龟类昆虫rna干扰的方法
CN109652420B (zh) * 2019-01-22 2022-06-14 汕头大学 一种高效抵抗WSSV的siRNA分子wsv147在制备抗WSSV制剂的应用
CN111304146B (zh) * 2020-03-11 2022-06-17 浙江省淡水水产研究所 一种促中华绒螯蟹造血组织发育免疫增强剂的筛选模型构建方法
CN113502337B (zh) * 2021-07-13 2022-03-22 华中农业大学 一种提高克氏原螯虾抗病能力的snp分子标记及应用
CN118679256A (zh) 2021-11-09 2024-09-20 微而广治疗有限公司 用于水产养殖的组合物
WO2024033948A1 (en) * 2022-08-11 2024-02-15 Karyotica Biologicals Private Limited Chimeric dna targeted to white spot syndrome
CN115589972B (zh) * 2022-09-07 2023-10-20 南京市水产科学研究所 一种基于池塘改造的螺蛳河蟹接力生态养殖方法
WO2024142041A1 (en) * 2022-12-29 2024-07-04 Viaqua Therapeutics Ltd. Compositions and methods for aquatic microsporidian infection
WO2024238491A2 (en) * 2023-05-12 2024-11-21 Redux Bio, Inc. Engineered microalgae and use in aquaculture
WO2025238646A1 (en) * 2024-05-17 2025-11-20 Viaqua Therapeutics Ltd. Stabilized chitosan-rna composition with magnesium
CN118600034A (zh) * 2024-06-21 2024-09-06 中国科学院南海海洋研究所 一种南美白对虾亚硝酸盐胁迫相关基因的snp标记、检测引物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270175A (en) * 1991-07-12 1993-12-14 Dna Plant Technology Corporation Methods and compositions for producing metabolic products for algae
GB9307408D0 (en) * 1993-04-08 1993-06-02 Danisco Transgenic plants
JPH09201196A (ja) * 1996-01-25 1997-08-05 Koyu Kaku 白斑症候群関連バキュロウイルスの同定、精製および検出
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
KR20000075076A (ko) 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
JP4786093B2 (ja) 1999-08-03 2011-10-05 インターベツト・インターナシヨナル・ベー・ベー 白点症候群ウイルス由来のタンパク質及びその使用
EP1235842A4 (en) * 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CN1651458A (zh) 2000-09-15 2005-08-10 阿克佐诺贝尔公司 虾白斑综合征病毒抗原蛋白及其用途
US20020164706A1 (en) * 2001-01-30 2002-11-07 Huang Lisa L. High level promoters from cyanobacteria
US6440466B1 (en) * 2001-02-21 2002-08-27 Council Of Scientific & Industrial Research Composition for treating white spot syndrome virus (WSSV) infected tiger shrimp penaeus monodon and a process for preparation thereof
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20040266708A1 (en) * 2002-01-29 2004-12-30 Paul Diamond Regulation of polynucleic acid activity and expression
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
EP1545600A4 (en) * 2002-09-16 2006-07-12 Advanced Bionutrition Corp PROTEIN AND PEPTIDE EXPRESSION FOR PASSIVE IMMUNITY
GB0306715D0 (en) 2003-03-24 2003-04-30 Novartis Ag Organic compounds
US20080194504A1 (en) 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2007089732A2 (en) * 2006-01-27 2007-08-09 Carnegie Institution Of Washington Improvement of levels and/or sustainability of dna-based gene expression
JP2008063302A (ja) * 2006-09-11 2008-03-21 Fisheries Research Agency クルマエビ属ホワイトスポット病用経口ワクチン
JP2008169131A (ja) * 2007-01-10 2008-07-24 Univ Of Miyazaki 甲殻類急性ウイルス血症に対するdnaワクチン
JP5404624B2 (ja) * 2007-08-01 2014-02-05 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ[2,1−c][1,4]ベンゾジアゼピン−グリコシドプロドラッグ

Also Published As

Publication number Publication date
JP2012036187A (ja) 2012-02-23
US8633028B2 (en) 2014-01-21
WO2005005613A3 (en) 2005-06-02
BRPI0412282A (pt) 2006-09-19
JP2007530414A (ja) 2007-11-01
WO2005005613A2 (en) 2005-01-20
US20050080032A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
JP2007530414A (ja) 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体
CN102906263B (zh) 用于控制蜂中的瓦螨的组合物
US9662348B2 (en) Compositions for controlling Varroa mites in bees
CN109689106B (zh) 治疗虾类病毒感染的组合物和方法
CN110997911A (zh) 水产养殖和其他动物系统中病原菌生物控制的新系统
TR201809375T4 (tr) Koloni halinde yaşayan böceklerde viral hastalığa karşı tolerans kazandırma yöntemi.
CN114134211B (zh) Usp30基因作为靶点在抑制塞内卡谷病毒复制中的应用
CN117982657A (zh) 靶向hrd1的试剂在抑制蚊媒病毒中的应用
US20050043263A1 (en) Use of double-stranded ribonucleic acid for inducing cell lysis
Apiratikul et al. Highly efficient double‐stranded RNA transfection of penaeid shrimp using cationic liposomes
CN1860220A (zh) dsRNA 诱导的在甲壳动物和其它无脊椎动物中的特异性和非特异性免疫及其中所用的生物送递载体
AU2018385901B2 (en) Methods for the production of sterile fish and other egg-producing aquatic animals and compounds for use in the methods
EP1974035B1 (fr) Arn interferents ciblant le gene de la nucleoproteine de morbillivirus
WO2024142041A1 (en) Compositions and methods for aquatic microsporidian infection
JP2025139727A (ja) Rna送達用組成物、rna送達用組成物の製造方法、水生動物の飼育方法及び水生動物
Iversen Immune Defense
KUMAR DEVELOPMENT AND NANO-DELIVERY OF CHITOSAN CONJUGATED STEROIDOGENIC ACUTE REGULATORY PROTEIN (StAR) GENE CONSTRUCT IN CLARIAS BATRACHUS
Čaracia The author retains ownership of the L'auteur conserve la propriété du
Wongwit Structural and physiological changes observed in schistosomula of Schistosoma mansoni as the effects of antisense oligodeoxynucleotides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120321

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121029

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees